Berlin, 16 July 2019 – Medios AG (‘Medios’), one of Germany’s leading specialty pharma companies, has gained an Austrian family office as an investor. The family office, whose name is being kept confidential as per the agreement, has acquired an equity stake of 100,000 shares.
The shares forming part of this stake were provided from share options of executives and management board members. These options had been granted as part of an employee participation programme in financial year 2016.
Matthias Gärtner, CFO of Medios AG: ‘We are happy to have gained an established Austrian family office as a long-term investor. This emphasises the appeal of Medios, also outside of Germany. In addition, we have again increased the company’s free float through this private placement. This will further strengthen the presence of Medios in capital markets, which will also benefit our existing shareholders.’
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients and GMP-certified provider of patient-specific therapies, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.
Medios AG is Germany’s first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).
Kirchhoff Consult AG
Tel.: +49 40 60918618
Fax: +49 40 60918660
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.